InsiderClue
Stocks · Health care · Pharmaceutical Preparations

NERVGEN PHARMA CORP.

NGEN Clue Score17
British Columbia, Canada Fiscal year ends December CIK 0001751912
$1.73 +0.00% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.73 −57.70% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 8 Jan 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Net income
Fiscal year 2024Net income−24.3EPS, diluted−0.36Fiscal year 2025Net income−44.1EPS, diluted−0.61
FY2024FY2025
Net income −24.3 −44.1
Growth
EPS, diluted −0.36 −0.61
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2024Operating cash flow−16.8Fiscal year 2025Operating cash flow−19.5
FY2024FY2025
Operating cash flow −16.8 −19.5

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash17.3Shareholders’ equity2.6Fiscal year 2025Cash22.1Shareholders’ equity3.5
FY2024FY2025
Cash 17.3 22.1
Shareholders’ equity 2.6 3.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
15.8 13.9
9.4 11.2
−24.3 −44.1
Growth
Per share
−0.36 −0.61
−0.36 −0.61
Growth
67.3 72.3
67.3 72.3
Growth +7.4%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 2 years on file.